TR200003435T2 - Yeni parçacıklı formülasyonlar - Google Patents
Yeni parçacıklı formülasyonlarInfo
- Publication number
- TR200003435T2 TR200003435T2 TR2000/03435T TR200003435T TR200003435T2 TR 200003435 T2 TR200003435 T2 TR 200003435T2 TR 2000/03435 T TR2000/03435 T TR 2000/03435T TR 200003435 T TR200003435 T TR 200003435T TR 200003435 T2 TR200003435 T2 TR 200003435T2
- Authority
- TR
- Turkey
- Prior art keywords
- particulate formulations
- new particulate
- animals
- high concentrations
- weak
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bu bulus zayif hidrofilik/zayif lipofilik bilesimlerin yüksek konsantrasyonlarini, biyo uygun hidrofobik alanlari olan bilesimleri hem hidrofobik hem de hidrofilik alanlari olan konjugatlarla birlestirerek, hayvanlara iletebilen araçlar saglamaktadir. Bu tür formülasyonlar hayvanlarda bir takim kullanimlar, özellikle buraya tedavi edici olarak kullanisli olan bilesimin yüksek konsantrasyonlarinin, asiri seviyeden yan etkileri olmaksizin, uygulanmasi için uygundur.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8610898P | 1998-05-20 | 1998-05-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200003435T2 true TR200003435T2 (tr) | 2001-03-21 |
Family
ID=22196324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2000/03435T TR200003435T2 (tr) | 1998-05-20 | 1999-05-19 | Yeni parçacıklı formülasyonlar |
Country Status (18)
Country | Link |
---|---|
US (1) | US6500461B2 (tr) |
EP (1) | EP1079812A4 (tr) |
JP (1) | JP2002535242A (tr) |
KR (1) | KR20010052368A (tr) |
CN (1) | CN1310612A (tr) |
AR (1) | AR019308A1 (tr) |
AU (1) | AU745015B2 (tr) |
BR (1) | BR9911031A (tr) |
CA (1) | CA2332545A1 (tr) |
EA (1) | EA200001109A1 (tr) |
EE (1) | EE200000693A (tr) |
ID (1) | ID28166A (tr) |
IL (1) | IL139541A0 (tr) |
NO (1) | NO20005832L (tr) |
PL (1) | PL344327A1 (tr) |
SK (1) | SK17422000A3 (tr) |
TR (1) | TR200003435T2 (tr) |
WO (1) | WO1999059550A1 (tr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
BR0212833A (pt) | 2001-09-26 | 2004-10-13 | Baxter Int | Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida |
US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050281740A1 (en) * | 2004-06-16 | 2005-12-22 | Glen Gong | Imaging damaged lung tissue |
US7553810B2 (en) | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
US20050281799A1 (en) | 2004-06-16 | 2005-12-22 | Glen Gong | Targeting damaged lung tissue using compositions |
US7608579B2 (en) | 2004-06-16 | 2009-10-27 | Pneumrx, Inc. | Lung volume reduction using glue compositions |
US7678767B2 (en) | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
EP1781182B1 (en) | 2004-07-08 | 2019-11-13 | PneumRx, Inc. | Pleural effusion treatment device |
JP2008506780A (ja) | 2004-07-19 | 2008-03-06 | セレーター ファーマスーティカルズ、インク. | 活性剤放出のための粒子状構築物 |
BRPI0600285C1 (pt) * | 2006-01-13 | 2011-10-11 | Brz Biotecnologia Ltda | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
WO2008141230A1 (en) | 2007-05-09 | 2008-11-20 | Lawrence Livermore National Security, Llc | Methods and systems for monitoring production of a target protein in a nanolipoprotein particle |
EP2176251B1 (en) | 2007-07-21 | 2012-02-08 | Albany Molecular Research, Inc. | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof |
EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | IMAGING PARTICLES |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
EP2674417A3 (en) | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
CN101945872B (zh) | 2008-01-11 | 2014-07-23 | 阿尔巴尼分子研究公司 | 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚 |
JP5539993B2 (ja) * | 2008-09-23 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 薬物送達のためのナノ担体 |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
AU2010207486B2 (en) | 2009-01-26 | 2013-03-07 | Israel Institute For Biological Research | Bicyclic heterocyclic spiro compounds |
CN101670095B (zh) * | 2009-04-13 | 2012-05-23 | 北京大学 | 一种用于栓塞治疗的药物组合物及其制备方法 |
MX2012000572A (es) | 2009-07-14 | 2012-05-08 | Albany Molecular Res Inc | Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos. |
AU2010339809B2 (en) | 2009-12-17 | 2016-05-05 | The Washington University | Antithrombotic nanoparticle |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
US9498439B2 (en) * | 2010-04-15 | 2016-11-22 | Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
KR101752944B1 (ko) | 2010-05-03 | 2017-07-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법 |
US8895055B2 (en) | 2011-12-21 | 2014-11-25 | The Regents Of The University Of California | Telodendrimer nanodiscs without apolipoprotein |
US9644038B2 (en) | 2011-12-21 | 2017-05-09 | The Regents Of The University Of California | Apolipoprotein nanodiscs with telodendrimer |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9642916B2 (en) | 2012-12-12 | 2017-05-09 | The Regents Of The University Of California | Porphyrin modified telodendrimers |
US11279749B2 (en) | 2015-09-11 | 2022-03-22 | Lawrence Livermore National Security, Llc | Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation |
WO2018053316A1 (en) | 2016-09-15 | 2018-03-22 | The Regents Of The University Of California | Improved hybrid telodendrimers |
WO2018204421A2 (en) | 2017-05-02 | 2018-11-08 | Lawrence Livermore National Security, Llc | Momp telonanoparticles, and related compositions, methods and systems |
CA3093340A1 (en) | 2018-03-20 | 2019-09-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
EP3906233B1 (en) | 2018-12-31 | 2024-01-31 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
MX9203504A (es) * | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
JP2687448B2 (ja) * | 1988-06-22 | 1997-12-08 | 大正製薬株式会社 | イブプロフェン徐放性製剤 |
JPH0429924A (ja) * | 1990-05-28 | 1992-01-31 | Terumo Corp | 脂溶性薬物含有注射用製剤 |
WO1991019486A1 (en) * | 1990-06-14 | 1991-12-26 | Kalmo Enterprises, Inc. | Stable aqueous drug suspensions |
US5599556A (en) * | 1991-12-31 | 1997-02-04 | Abbott Laboratories | Prolamine coatings for taste masking |
NZ253999A (en) * | 1992-08-05 | 1996-07-26 | Faulding F H & Co Ltd | Pelletised substained release medicament |
US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5776486A (en) | 1993-05-28 | 1998-07-07 | Aphios Corporation | Methods and apparatus for making liposomes containing hydrophobic drugs |
US5478860A (en) | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
KR100401220B1 (ko) * | 1995-09-12 | 2004-03-20 | 더 리포좀 컴퍼니, 인코퍼레이티드 | 가수분해를촉진시키는소수성탁산유도체 |
HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
-
1999
- 1999-05-19 WO PCT/US1999/010975 patent/WO1999059550A1/en not_active Application Discontinuation
- 1999-05-19 EE EEP200000693A patent/EE200000693A/xx unknown
- 1999-05-19 JP JP2000549215A patent/JP2002535242A/ja active Pending
- 1999-05-19 AR ARP990102392A patent/AR019308A1/es unknown
- 1999-05-19 CN CN99808935A patent/CN1310612A/zh active Pending
- 1999-05-19 PL PL99344327A patent/PL344327A1/xx unknown
- 1999-05-19 EA EA200001109A patent/EA200001109A1/ru unknown
- 1999-05-19 CA CA002332545A patent/CA2332545A1/en not_active Abandoned
- 1999-05-19 EP EP99925661A patent/EP1079812A4/en not_active Withdrawn
- 1999-05-19 US US09/314,338 patent/US6500461B2/en not_active Expired - Fee Related
- 1999-05-19 SK SK1742-2000A patent/SK17422000A3/sk unknown
- 1999-05-19 AU AU41906/99A patent/AU745015B2/en not_active Ceased
- 1999-05-19 BR BR9911031-8A patent/BR9911031A/pt not_active IP Right Cessation
- 1999-05-19 ID IDW20002634A patent/ID28166A/id unknown
- 1999-05-19 IL IL13954199A patent/IL139541A0/xx unknown
- 1999-05-19 TR TR2000/03435T patent/TR200003435T2/tr unknown
- 1999-05-19 KR KR1020007013002A patent/KR20010052368A/ko not_active Application Discontinuation
-
2000
- 2000-11-17 NO NO20005832A patent/NO20005832L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200001109A1 (ru) | 2001-06-25 |
WO1999059550A1 (en) | 1999-11-25 |
AU745015B2 (en) | 2002-03-07 |
CA2332545A1 (en) | 1999-11-25 |
EE200000693A (et) | 2002-04-15 |
NO20005832D0 (no) | 2000-11-17 |
PL344327A1 (en) | 2001-10-22 |
EP1079812A4 (en) | 2001-12-12 |
KR20010052368A (ko) | 2001-06-25 |
CN1310612A (zh) | 2001-08-29 |
JP2002535242A (ja) | 2002-10-22 |
AU4190699A (en) | 1999-12-06 |
EP1079812A1 (en) | 2001-03-07 |
SK17422000A3 (sk) | 2001-09-11 |
US20020034536A1 (en) | 2002-03-21 |
IL139541A0 (en) | 2004-02-08 |
AR019308A1 (es) | 2002-02-13 |
NO20005832L (no) | 2001-01-18 |
US6500461B2 (en) | 2002-12-31 |
ID28166A (id) | 2001-05-10 |
BR9911031A (pt) | 2002-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200003435T2 (tr) | Yeni parçacıklı formülasyonlar | |
CY1119742T1 (el) | Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου | |
ATE337019T1 (de) | Geladene lipide und deren verwendung | |
PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
TR199800436A2 (tr) | Primidin türevlerinin kanserin önlenmesi için kullanilmasi. | |
BRPI0407922A (pt) | derivados de isoquinolina e métodos de uso destes | |
TR199903331T2 (tr) | Farnesil protein transferas engelleyicileri. | |
TR200101499T1 (tr) | Azepinoindol türevleri, hazırlanmaları ve kullanımları. | |
CY1105896T1 (el) | Χρησιμοποιηση ιδεβενονης δια την προστασια σκευασματων | |
CY1110914T1 (el) | Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
DE60020812D1 (de) | Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel | |
PA8459901A1 (es) | Derivados de resorcinol | |
PT842934E (pt) | Agonistas de 5-ht1f | |
DK0998460T3 (da) | Hidtil ukendte tetrazolderivater | |
DE69921318D1 (de) | Tensid für äusserlich anzuwendende hautpräparate und diese beinhaltende äusserlich anzuwendende hautpräparate | |
ATE413179T1 (de) | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden | |
TR200200066T2 (tr) | Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri | |
TR200102041T2 (tr) | Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar | |
ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. | |
TR200103457T2 (tr) | 4-Fenil-Pirimidin Türevleri. | |
PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
IT1270618B (it) | Proteine ad attivita' antitumorale | |
ATE199641T1 (de) | Terpenderivate (sarcodictyine) als antikrebsmittel | |
BR0011261B1 (pt) | composiÇço oral compreendendo perlita, e, uso de perlita. | |
FR2857597B1 (fr) | Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie. |